Model Studies of Cyclophosphamide Resistance in Human Myeloid Leukemia

  • Borje S. Andersson
  • David Murray
Part of the Cancer Treatment and Research book series (CTAR, volume 112)


Cyclophosphamide (CP), 4-hydroperoxycyclophosphamide (4HC), mafosfamide, and ifosphamide are antineoplastic alkylating agents collectively referred to as oxazaphosphorines. Oxazaphosphorines are used in the treatment of many types of cancer, including neo-adjuvant, adjuvant and high-dose treatment for breast tumors, salvage chemotherapy for a variety of solid tumors, and high-dose conditioning therapy of patients undergoing hematopoietic stem cell transplantation1, 2. In the latter context, these drugs are widely used for the treatment of myeloid leukemias, which represent the focus of this chapter


Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Nucleotide Excision Repair Aldehyde Dehydrogenase Xeroderma Pigmentosum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    DeVita VT Jr, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology, 6th ed., Lippincott, Williams and Wilkins, Philadelphia, PA, 2001.Google Scholar
  2. 2.
    Holland JF, Frei E III, Cancer Medicine, e.5, Decker B.C., Inc., Hamilton, Ontario, Canada, 2000.Google Scholar
  3. 3.
    List AF, Kopecky KJ, Willman CLet al.Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98,3212–3220, 2001.PubMedCrossRefGoogle Scholar
  4. 4.
    Ohno N, Tani A, Chen ZS, et aL Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res, 10:3120–3126, 2001.Google Scholar
  5. 5.
    Sreerama L, Sladek NE. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired, metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens. Cancer Chemother Pharmacol, 47:255–262, 2001.PubMedCrossRefGoogle Scholar
  6. 6.
    Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res, 44:5156–5160, 1984.PubMedGoogle Scholar
  7. 7.
    Friedman HS, Colvin OM, Kaufmann SHet al.Cyclophosphamide resistance in medulloblastoma. Cancer Res, 52:5373–5378, 1992.PubMedGoogle Scholar
  8. 8.
    Sreerama L, Sladek NE. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorinespecific acquired resistance. Cancer Res, 54:2176–2185, 1994.PubMedGoogle Scholar
  9. 9.
    Rekha GK, Sreerama L, Sladek NE. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem Pharmacol, 48:1943–1952, 1994.PubMedCrossRefGoogle Scholar
  10. 10.
    de Groot CJ, Martens ACM, Hagenbeek A. Aldehyde dehydrogenase involvement in a variant of the brown Norway rat acute myeloid leukaemia (BNML) that acquired cyclophosphamide resistance in vivo. Eur J Cancer, 30A:2137–2143, 1994.PubMedCrossRefGoogle Scholar
  11. 11.
    Gamcsik MP, Dolan ME, Andersson BS, Murray D. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr Pharm Des, 5:587–605, 1999.PubMedGoogle Scholar
  12. 12.
    Hipkens JH, Struck RF, Gurtoo HL. Role of aldehyde dehydrogenase in the metabolism-dependent biological activity of cyclophosphamide. Cancer Res, 41:3571–3583, 1981.PubMedGoogle Scholar
  13. 13.
    Lin K-H, Lindahl R. Role of aldehyde dehydrogenase activity in cyclophosphamide metabolism in rat hepatoma cell lines. Biochem Pharmacol, 36:3305–3307, 1987.PubMedCrossRefGoogle Scholar
  14. 14.
    Richardson ME, Siemann DW. Thiol-related mechanisms of resistance in a murine tumor model. Int J Radiat Oncol Biol Phys, 29:387–392, 1994.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoy CA, Thompson LH, Mooney CL, Salazar EP. Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res, 45:1737–1743, 1985.PubMedGoogle Scholar
  16. 16.
    Andersson BS, Sadeghi T, Siciliano MJet al.Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol, 38:406–416, 1996.PubMedCrossRefGoogle Scholar
  17. 17.
    Murray D, Vallee-Lucic L, Rosenberg E, Andersson B. Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res, 22:21–26, 2002.Google Scholar
  18. 18.
    Thompson LH. Nucleotide excision repair. Its relation to human disease. In: DNA Damage and Repair, Vol. 2: DNA Repair in Higher Eukaryotes, IA Nickoloff, MF Hoekstra (eds.), Humana Press, Totowa, NJ, 335–393, 1998.Google Scholar
  19. 19.
    Busch DB, van Vuuren H, de Wit Jet al.Phenotypic heterogeneity in nucleotide excision repair mutants of rodent complementation groups 1 and 4. Mutat Res, 383:91–106, 1997.PubMedCrossRefGoogle Scholar
  20. 20.
    Panasci L, Paiement JP, Christodoulopoulos Get al.Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res, 7:454–461, 2001.PubMedGoogle Scholar
  21. 21.
    Andersson BS, Beran M, Pathak Set al.Ph-positive chronic myeloid leukemia with near-haploid conversion in vivo and establishment of a continuously growing cell line with similar cytogenetic pattern. Cancer Genet Cytogenet, 24:335–343, 1987.PubMedCrossRefGoogle Scholar
  22. 22.
    Andersson BS, Collins VP, Kurzrock Ret al.KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. Leukemia, 9:2100–2108, 1995.PubMedGoogle Scholar
  23. 23.
    Andersson BS, Mroue M, Britten R, Murray D. The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogs. Cancer Res, 54:5394–5400, 1994.PubMedGoogle Scholar
  24. 24.
    Andersson BS, Mroue M, Britten RAet al.Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line. Acta Oncol, 34:247–251, 1995.PubMedCrossRefGoogle Scholar
  25. 25.
    Kantarjian HM, O’Brien SO, Smith TLet al.Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol, 18:547–561, 2000.PubMedGoogle Scholar
  26. 26.
    Kantarjian HM, Walters RS, Keating MJet al.Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard-and high-risk acute lymphocytic leukemia. J Clin Oncol, 8:994–1004, 1990.PubMedGoogle Scholar
  27. 27.
    Wang Y, Farquhar D. Aldophosphamide acetal diacetate and structural analogues: Synthesis and cytotoxicity studies. J Med Chem, 34:197–203, 1991.PubMedCrossRefGoogle Scholar
  28. 28.
    O’Connor PM, Kohn KW. Comparative pharmacokinetics of DNA lesion formation and removal following treatment of L1210 cells with nitrogen mustards. Cancer Commun, 2:387–394, 1990.PubMedGoogle Scholar
  29. 29.
    Caldecott K, Jeggo P. Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents. Mutat Res, 255:111–121, 1991.PubMedCrossRefGoogle Scholar
  30. 30.
    De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol, 20:7980–7990, 2000.PubMedCrossRefGoogle Scholar
  31. 31.
    Bresnick EH, Chu J, Christensen HMet al.Linking Notch signaling, chromatin remodeling, and T-cell leukemogenesis. J Cell Biochern Suppl, 35:46–53, 2000.CrossRefGoogle Scholar
  32. 32.
    Joutel A, Tournier-Lasserve E. Notch signalling pathway and human diseases. Semin Cell Dev Biol, 9:619–625, 1998.PubMedCrossRefGoogle Scholar
  33. 33.
    Sreerama L, Sladek NE. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem Pharmacol, 45:2487–2505, 1993.PubMedCrossRefGoogle Scholar
  34. 34.
    Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases: The first enzymatic step in mercapturic acid formation. J Biol Chem, 249:7130–7139, 1974.PubMedGoogle Scholar
  35. 35.
    Andersson BS, Bullard C, Farquhar D, Murray D. Mechanisms of acquired resistance to cyclophosphamide analogs in human myeloid leukemia. Proc Amer Assoc Cancer Res, Abstract 2782, 1992.Google Scholar
  36. 36.
    Dong Q, Bullock N, Ali-Osman Fet al.Repair analysis of 4- hydroperoxycyclophosphamide-induced DNA interstrand crosslinking of the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines. Cancer Chemother Pharmacol, 37:242–246, 1996.PubMedCrossRefGoogle Scholar
  37. 37.
    O’Connor PM, Ferris DK, White GAet al.Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ, 3:43–52, 1992.PubMedGoogle Scholar
  38. 38.
    Pollack JR, Perou CM, Alizadeh AAet al.Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nature Genet, 23:41–46, 1999.PubMedCrossRefGoogle Scholar
  39. 39.
    Hui AB, Lo KW, Yin XLet al.Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest, 81:717–723, 2001.Google Scholar
  40. 40.
    Deftos ML, He YW, Ojala EW, Bevan MJ. Correlating notch signaling with thymocyte maturation. Immunity, 9:777–786, 1998.PubMedCrossRefGoogle Scholar
  41. 41.
    Weinmaster G. Notch signal transduction: a real rip and more. Curr Opin Genet Dev, 10:363–369, 2000.PubMedCrossRefGoogle Scholar
  42. 42.
    Callahan R, Raafat A. Notch signaling in mammary gland tumorigenesis. J Mammary Gland Biol Neoplasia, 6:23–36, 2001.PubMedCrossRefGoogle Scholar
  43. 43.
    Frisen J, Lendahl U. Oh no, Notch again! Bioessays, 23:3–7, 2001.PubMedCrossRefGoogle Scholar
  44. 44.
    Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science, 257:967–971, 1992.PubMedCrossRefGoogle Scholar
  45. 45.
    Iwai N, Inagami T. Isolation of preferentially expressed genes in the kidneys of hypertensive rats. Hypertension, 17:161–169, 1991.PubMedCrossRefGoogle Scholar
  46. 46.
    Iwai N, Ohmichi N, Hanai Ket al.Human SA gene locus as a candidate locus for essential hypertension. Hypertension, 23:375–380, 1994.PubMedCrossRefGoogle Scholar
  47. 47.
    Nagase T, Ishikawa K, Miyajima Net al.Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA Res, 5:31–39, 1998.PubMedCrossRefGoogle Scholar
  48. 48.
    Kurihara LJ, Semenova E, Miller Wet al.Candidate genes required for embryonic development: a comparative analysis of distal mouse chromosome 14 and human chromosome 13q22. Genomics, 79:154–161, 2002.PubMedCrossRefGoogle Scholar
  49. 49.
    Tanoue T, Moriguchi T, Nishida E. Molecular cloning and characterization of a novel dual specificity phosphatase, MKP-5. J Biol Chem, 274:19949–19956, 1999.PubMedCrossRefGoogle Scholar
  50. 50.
    Wiemann S, Weil B, Wellenreuther Ret al.Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs. Genome Res, 11:422–435, 2001.PubMedCrossRefGoogle Scholar
  51. 51.
    Perraud AL, Fleig A, Dunn CAet al.ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. Nature, 411:595–599, 2001.PubMedCrossRefGoogle Scholar
  52. 52.
    Domeyer BE, Sladek NE. Metabolism of 4-hydroxycyclophosphamide/aldophosphamide in vitro. Biochem Pharmacol, 29:2903–2912, 1980.PubMedCrossRefGoogle Scholar
  53. 53.
    Sladek NE. Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines. In: Anticancer Drugs: Reactive Metabolism and Drug Interactions, G Powis (ed.), Pergamon Press, New York, NY, 79–156, 1994.Google Scholar
  54. 54.
    Ferry KV, Ozols RF, Hamilton TCet al.Expression of nucleotide excision repair genes in CDDP-sensitive and resistant human ovarian cancer cell lines. Proc Amer Assoc Cancer Res, Abstract 2492, 1996.Google Scholar
  55. 55.
    Reed E. Ovarian cancer: Molecular abnormalities. In: Encyclopedia of Cancer, Vol. II, JR Bertino (ed.), Academic Press, San Diego, CA, 1192–1200, 1997.Google Scholar
  56. 56.
    Davidoff AN, Mendelow BV. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide. Exp Hematol, 21:922–927, 1993.PubMedGoogle Scholar
  57. 57.
    Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res, 7:3580–3589, 2001.PubMedGoogle Scholar
  58. 58.
    Lopes EC, Garcia MG, Vellon Let al.Correlation between decreased apoptosis and multidrug resistance (MDR) in murine leukemic T cell lines. Leukemia Lymphoma, 42:775–787, 2001.PubMedCrossRefGoogle Scholar
  59. 59.
    Klein A, Miera 0, Bauer 0et al.Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair. Leukemia, 14:40–46, 2000.PubMedCrossRefGoogle Scholar
  60. 60.
    Skorski T, Nieborowska-Skorska M, Wlodarski Pet al.Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. J Natl Cancer Inst, 89:124–133, 1997.PubMedCrossRefGoogle Scholar
  61. 61.
    Bullock G, Tang C, Tourkina Eet al.Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-induced programmed cell death or apoptosis in human myeloid leukemia cells. Exp Hematol, 21:1640–1647, 1993.PubMedGoogle Scholar
  62. 62.
    Inoue S, Salah-Eldin AE, Omoteyama K. Apoptosis and anticancer drug resistance. Human Cell. 14:211–221, 2001.PubMedGoogle Scholar
  63. 63.
    Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol, 11:S22–26, 2001.PubMedGoogle Scholar
  64. 64.
    Mow BM, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Curr Opin Oncol, 13:453–462, 2001.PubMedCrossRefGoogle Scholar
  65. 65.
    Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res, 4:1–6, 1998.Google Scholar
  66. 66.
    Munker R, Zhao S, Jiang Set al.Further characterization of cyclophosphamide resistance: expression of CD95 and of bcl-2 in a CML cell line. Leukemia Res, 22:1073–1077, 1998.CrossRefGoogle Scholar
  67. 67.
    Shima Y, Nishimoto N, Ogata Aet al.Myeloma cells express Fas antigen (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood, 85:757–764, 1995.PubMedGoogle Scholar
  68. 68.
    Debatin KM, Krammer PH. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a bcl-2 independent anti-apoptotic program. Leukemia, 9:815–820, 1995.PubMedGoogle Scholar
  69. 69.
    Sumantran VN, Elovega MW, Nunez Get al.Over-expression of Bc1-xssensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res, 55:2507–2510, 1995.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Borje S. Andersson
    • 1
  • David Murray
    • 2
  1. 1.Department of Blood and Marrow TransplantationThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Division of Experimental Oncology, Department of OncologyUniversity of Alberta and Department of Experimental OncologyAlbertaCanada

Personalised recommendations